Synthetic Biologics (SYN) Sees Unusually-High Trading Volume

Share on StockTwits

Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw an uptick in trading volume on Thursday . 3,106,525 shares changed hands during trading, an increase of 838% from the previous session’s volume of 331,204 shares.The stock last traded at $0.81 and had previously closed at $0.69.

A number of research firms have recently issued reports on SYN. Zacks Investment Research raised shares of Synthetic Biologics from a “hold” rating to a “strong-buy” rating and set a $0.75 target price for the company in a report on Thursday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Synthetic Biologics in a report on Tuesday, November 20th.

TRADEMARK VIOLATION NOTICE: “Synthetic Biologics (SYN) Sees Unusually-High Trading Volume” was first posted by Macon Daily and is the property of of Macon Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://macondaily.com/2019/03/14/synthetic-biologics-syn-sees-unusually-high-trading-volume.html.

About Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Further Reading: What is Net Asset Value (NAV)?

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply